VerImmune Inc Appoints Oncology Veteran as Interim Chief Business Officer

A biotech industry veteran in oncology to lead business development and alliance-building efforts for VerImmune’s proprietary Anti-tumor Immune Redirection (AIR) platform

Baltimore, Maryland – Feb 14th, 2020 – VerImmune, Inc., a privately-owned immuno-oncology biotechnology company developing a first-in-class broad-spectrum cancer therapy for solid tumors based on “Anti-tumor Immune Redirection”, announced the appointment of Ms. Debra Bowes, MBEE., as interim Chief Business Officer. Ms. Bowes brings to the team more than 25 years’ experience in corporate and product strategy, licensing/business development and funding and in the creation of partnerships to advance the development and commercialization of biopharmaceutical products, with a main emphasis in oncology.

Before joining VerImmune, Ms. Bowes was the Chief Business Officer for MaxCyte CARMA. She built the drug development team, led the company to file their first cell therapy IND and initiated their first clinical trial. In addition, she negotiated and closed 3 cell therapy platform licenses with notable cell therapy companies. Prior to Maxcyte CARMA, Ms. Bowes was interim President and Chief Executive Officer of CapGenesis Pharma, in Bethesda, MD, Ms. Bowes has also held positions of increasing leadership at CBLI Pharmaceuticals, MedImmune, Pfizer, and Centocor. Debra is also former National President, current National Board Member and member of Nat’l Director Emeritus for Women in BIO. She has been an industry speaker since 2005 and currently serves on Industry Corporate Boards. Debra holds a Bachelor of Science degree in cell biology from the University of Cincinnati, a Medical Technologist (M.T.) certification from the American Society of Clinical Pathologists and an MBEE from John’s Hopkins University.

 “I am excited to have a leader of Debra’s caliber to have chosen to join VerImmune at this exciting time,” said Scientific Founder and acting CEO Joshua Wang. “we have demonstrated successful in vivo pre-clinical studies and we must now focus on our advanced development to IND, a prelude to clinical studies as well as commercialization strategy. Deb will be an invaluable member, on relationships with partners and investors to further develop our immuno-oncology AIR product pipeline”

In her new role at VerImmune, Ms. Bowes will lead the strategic planning and execution of all business development activities related to VerImmune’s AIR program. VerImmune’s proprietary AIR platform technology leverages the patient’s own preexisting immune memory from past infections or childhood vaccines and repurposes it to target their own solid tumors.

About VerImmune 
Located in Baltimore Maryland within the Johns Hopkin’s 1812 Fastforward incubator, VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This strategy utilizes a proprietary tumor-specific, tumor type agnostic, virus-inspired platform termed Anti-tumor Immune Redirectors (AIRTM) that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors. This unique mechanism of action allows differentiation within the competitive Immuno-Oncology market. Importantly, it potentially changes the treatment paradigm for many patients who have untreatable cancers due to limited options or resistance. The company initially raised a seed round and demonstrated proof-of-concept in preclinical studies for its first product candidate, VERI-101; it will be seeking additional funding in 2020 to move VERI-101 to an IND.

For more information visit: 

See the Original Article Here

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.